Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

<p>CONSORT Diagram</p>

Spremljeno u:

Bibliografski detalji
Glavni autor:	Aurelius Omlin (14971513) (author)
Daljnji autori:	Richard Cathomas (14971516) (author), Gunhild von Amsberg (14971519) (author), Christoph Reuter (14971522) (author), Susan Feyerabend (14971525) (author), Wolfgang Loidl (14971528) (author), Martin Boegemann (14971531) (author), Anja Lorch (14971534) (author), Axel Heidenreich (14971537) (author), Igor Tsaur (14971540) (author), Julian Larcher-Senn (14971543) (author), Stefan A.J. Buck (14971546) (author), Ron H.J. Mathijssen (14971549) (author), Ulrich Jaehde (14971552) (author), Silke Gillessen (14971555) (author), Markus Joerger (14971558) (author)
Izdano:	2025
Teme:	Cancer Therapeutic Research and Development Clinical Research and Trials Methods and Technology Chemotherapy Clinical-Stage Research Computational Methods Algorithms Genitourinary Cancers Prostate cancer Pharmacology Pharmacokinetics and pharmacodynamics
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!

Slični predmeti

Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
od: Aurelius Omlin (14971513)
Izdano: (2025)

Figure 1 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
od: Monica M. Mita (21585118)
Izdano: (2025)

Figure 2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
od: Monica M. Mita (21585118)
Izdano: (2025)

Figure 3 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
od: Monica M. Mita (21585118)
Izdano: (2025)

Figure 4 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
od: Monica M. Mita (21585118)
Izdano: (2025)

Figure S1 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
od: Monica M. Mita (21585118)
Izdano: (2025)

Figure S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
od: Monica M. Mita (21585118)
Izdano: (2025)

Figure S3 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
od: Monica M. Mita (21585118)
Izdano: (2025)

Figure S4 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
od: Monica M. Mita (21585118)
Izdano: (2025)

Figure S5 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
od: Monica M. Mita (21585118)
Izdano: (2025)

Table 1 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
od: Monica M. Mita (21585118)
Izdano: (2025)

Table 2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
od: Monica M. Mita (21585118)
Izdano: (2025)

Table 3 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
od: Monica M. Mita (21585118)
Izdano: (2025)

Table 4 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
od: Monica M. Mita (21585118)
Izdano: (2025)

Table S1 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
od: Monica M. Mita (21585118)
Izdano: (2025)

Table S2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
od: Monica M. Mita (21585118)
Izdano: (2025)

Table S3 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2
od: Monica M. Mita (21585118)
Izdano: (2025)

Figure 3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
od: Eric D. Eisenmann (15013737)
Izdano: (2025)

Supplementary Figure S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
od: Eric D. Eisenmann (15013737)
Izdano: (2025)

Supplementary Figure S2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
od: Eric D. Eisenmann (15013737)
Izdano: (2025)

Supplementary Figure S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
od: Eric D. Eisenmann (15013737)
Izdano: (2025)

Supplementary Figure S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
od: Eric D. Eisenmann (15013737)
Izdano: (2025)

Figure 1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
od: Eric D. Eisenmann (15013737)
Izdano: (2025)

Figure 2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
od: Eric D. Eisenmann (15013737)
Izdano: (2025)

Supplementary Figure S1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
od: Eric D. Eisenmann (15013737)
Izdano: (2025)

Supplementary Figure S2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
od: Eric D. Eisenmann (15013737)
Izdano: (2025)

Supplementary Figure S3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
od: Eric D. Eisenmann (15013737)
Izdano: (2025)

Supplementary Figure S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
od: Eric D. Eisenmann (15013737)
Izdano: (2025)

Table 1 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
od: Eric D. Eisenmann (15013737)
Izdano: (2025)

Table 2 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
od: Eric D. Eisenmann (15013737)
Izdano: (2025)

Table 3 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant <i>TP53</i> and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years
od: Eric D. Eisenmann (15013737)
Izdano: (2025)

Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
od: Zachary Quinn (15052893)
Izdano: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
od: Ulka N. Vaishampayan (15051039)
Izdano: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
od: Ulka N. Vaishampayan (15051039)
Izdano: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
od: Ulka N. Vaishampayan (15051039)
Izdano: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
od: Ulka N. Vaishampayan (15051039)
Izdano: (2025)

Figure 1 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
od: Diana M. Carvalho (5608127)
Izdano: (2025)

Figure 2 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
od: Diana M. Carvalho (5608127)
Izdano: (2025)

Figure 3 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
od: Diana M. Carvalho (5608127)
Izdano: (2025)

Figure 4 from Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma
od: Diana M. Carvalho (5608127)
Izdano: (2025)